In Q4 2024 AMN Healthcare posted meaningful sequential revenue growth for the first time in 2 years, suggesting its cyclical decline might be coming to an end. A variety of indicators shows stabilisation in the market, but an upward inflection doesn't seem imminent. Long-term growth and margin drivers like platformization and a larger tech segment are intact, but acquisitions are on hold due to high debt.
AMN Healthcare's dismal results in the majority of its segments led to a soft overall fourth-quarter performance.
Although the revenue and EPS for AMN Healthcare (AMN) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
AMN Healthcare Services (AMN) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.52 per share. This compares to earnings of $1.32 per share a year ago.
Quarterly revenue of $735 million; GAAP loss of ($4.90)/share and adjusted EPS of $0.75
Here is a sneak peek into how three MedTech stocks, GKOS, ITGR and AMN, are expected to fare in their quarterly results, slated to be released tomorrow.
Madison Investments, an investment advisory firm, published its fourth-quarter 2024 letter to investors for the "Madison Small Cap Fund." You can download the letter here. The fund had a successful year, achieving impressive returns both in the fourth quarter and throughout the entire year.
Polen Capital, an investment management firm, published its fourth-quarter 2024 investor letter for the "Polen U.S. Small Company Growth Strategy." You can download the letter here. The Russell 2000 Growth Index shows that U.S. small cap growth stocks grew by 1.7% in the fourth quarter and saw a 15% increase over the entire year of 2024.
Abercrombie & Fitch and AMN Healthcare Services have been featured as Zacks' Bull and Bear of the Day.
Shares have tumbled to new 5-year lows.